X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (91) 91
male (79) 79
female (77) 77
middle aged (71) 71
adult (64) 64
aged (62) 62
hematology (57) 57
index medicus (51) 51
oncology (50) 50
chemotherapy (47) 47
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
treatment outcome (42) 42
prognosis (35) 35
disease-free survival (32) 32
aged, 80 and over (27) 27
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
disease (24) 24
neoplasm staging (23) 23
survival (23) 23
rituximab (22) 22
adolescent (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (20) 20
follow-up studies (20) 20
therapy (18) 18
cyclophosphamide - administration & dosage (17) 17
doxorubicin - administration & dosage (17) 17
non-hodgkins-lymphoma (17) 17
cancer (16) 16
survival analysis (16) 16
vincristine - administration & dosage (16) 16
fludarabine (15) 15
hodgkin disease - drug therapy (15) 15
kaplan-meier estimate (15) 15
lymphomas (15) 15
prednisone - administration & dosage (15) 15
combined modality therapy (14) 14
prospective studies (14) 14
bleomycin - administration & dosage (13) 13
care and treatment (13) 13
radiotherapy (13) 13
retrospective studies (13) 13
survival rate (13) 13
hodgkin disease - pathology (12) 12
young adult (12) 12
multivariate analysis (11) 11
vidarabine - analogs & derivatives (11) 11
cyclophosphamide (10) 10
drug administration schedule (10) 10
remission induction (10) 10
toxicity (10) 10
trial (10) 10
chop (9) 9
methotrexate - administration & dosage (9) 9
predictive value of tests (9) 9
cyclophosphamide - adverse effects (8) 8
doxorubicin - adverse effects (8) 8
etoposide - administration & dosage (8) 8
follicular lymphoma (8) 8
italy (8) 8
lymphoma, large b-cell, diffuse - drug therapy (8) 8
lymphoma, non-hodgkin - drug therapy (8) 8
positron-emission-tomography (8) 8
recurrence (8) 8
regimen (8) 8
rituximab - administration & dosage (8) 8
vinblastine - administration & dosage (8) 8
antibodies, monoclonal, murine-derived - administration & dosage (7) 7
b-cell lymphoma (7) 7
classification (7) 7
dacarbazine - administration & dosage (7) 7
disease progression (7) 7
dosage and administration (7) 7
doxorubicin (7) 7
doxorubicin - therapeutic use (7) 7
hodgkin disease - mortality (7) 7
leukemia, lymphocytic, chronic, b-cell - pathology (7) 7
lymphoma (7) 7
salvage therapy (7) 7
transplantation, autologous (7) 7
vidarabine - administration & dosage (7) 7
vincristine - adverse effects (7) 7
1st-line treatment (6) 6
abridged index medicus (6) 6
analysis (6) 6
bleomycin - adverse effects (6) 6
bleomycin - therapeutic use (6) 6
chronic lymphocytic-leukemia (6) 6
combination (6) 6
cyclophosphamide - therapeutic use (6) 6
epirubicin - administration & dosage (6) 6
experience (6) 6
fluorodeoxyglucose f18 (6) 6
follow-up (6) 6
hodgkin disease - diagnostic imaging (6) 6
hodgkin's disease (6) 6
incidence (6) 6
lymphoma, b-cell - drug therapy (6) 6
lymphoma, follicular - drug therapy (6) 6
methotrexate (6) 6
multiple myeloma (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 319 - 331
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2018, Volume 183, Issue 5, pp. 755 - 765
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1175 - 1181
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 10, pp. e467 - e479
Journal Article
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2011, Volume 152, Issue 5, pp. 551 - 560
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 10/2011, Volume 19, Issue 10, pp. 1505 - 1510
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article